Global Congenital Adrenal Hyperplasia Treatment Market Report and Forecast 2024-2032

Global Congenital Adrenal Hyperplasia Treatment Market Outlook

The global congenital adrenal hyperplasia treatment market is expected to grow at a CAGR of 7.75% during the forecast period 2024-2032. The growth can be attributed to the increasing prevalence of congenital adrenal hyperplasia and genetic abnormalities, government funding and assistance, along with joint research with large pharmaceutical businesses. 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Congenital Adrenal Hyperplasia Treatment Market Insights

Congenital adrenal hyperplasia (CAH) is a collection of hereditary disorders affecting the adrenal glands, which are a pair of walnut-sized structures located above the kidneys. Important hormones produced by the adrenal glands include the following:

• Mineralocorticoids, such as aldosterone, regulate sodium, and potassium levels.

• Cortisol regulates the body's response to disease or stress.

• Androgens, such as testosterone, are male sex hormones that are essential for both male and female growth and development.

The most common cause of CAH is a deficiency in the enzyme 21-hydroxylase. CAH is also known as 21-hydroxylase deficiency. The body requires this enzyme to produce enough levels of hormones. Other, far uncommon enzyme deficits can also induce CAH. 

Parents who have CAH or are carriers of the disorder’s genetic alteration are most likely to increase the chances of CAH prevalence.

95% of all CAH cases are of two categories which are classical congenital adrenal hyperplasia and non-classic congenital adrenal hyperplasia. The more dangerous form of CAH is known as classic CAH. It can result in adrenal problems such as shock and coma. It can be lethal if not detected and treated promptly and is often diagnosed at birth. Classic CAH is divided into two subtypes: Saltwasting CAH and Simple—virilizing CAH. On the other hand, non-classic CAH is the mildest form of CAH.

Complications Associated with Congenital Adrenal Hyperplasia

Classic congenital adrenal hyperplasia (CAH) produces excessive water and salt loss in the urine. People are at risk of significant consequences such as electrolyte imbalances like potassium. These imbalances, if left unchecked, can result in arrhythmia, cardiac arrest, and death.

Non-classic CAH might also cause difficulties if left untreated. It can result in the following symptoms in people who were assigned male at birth (AMAB) early onset of puberty and short stature. With people assigned female at birth (AFAB) include symptoms like permanent male physical traits, irregular menstruation, and infertility.

According to the congenital adrenal hyperplasia treatment market research report, the market can be categorised into the following segments:  

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diagnosis Method

• Prenatal Testing
  • Aminocentesis
  • Chorionic Villus Sampling
• Physical Exam
• Blood and Urine Tests
• Genetics Testing

Market Breakup by Treatment Method

• Medications

• Physical Exams

• Reconstructive Surgery

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Congenital Adrenal Hyperplasia Epidemiology

In the United States and Europe, 1 in every 10,000 to 15,000 persons has classic CAH. Non-classic CAH affects around 1 out of every 100 to 200 persons. CAH, both classic and non-classic, affects people all over the world. The prevalence of the salt-wasting type of this condition may be as high as 1 in 282 Yupik Eskimos. Other types of CAH are far more uncommon. Non-classical CAH, on the other hand, affects around 1 in 100 to 1 in 200 people in the general population.

Global Congenital Adrenal Hyperplasia Treatment Market Drivers

The increasing prevalence of congenital adrenal hyperplasia and genetic abnormalities is driving the growth of the global congenital adrenal hyperplasia treatment market. Many government organisations are assisting R&D and manufacturers by providing research grants. The rising demand for better treatment and increased government backing has fuelled the growth of the global market. Government financing and assistance, along with collaborative research with large pharmaceutical firms, are expected to promote the market growth further in the future. 

Therapeutic Landscape  of the Congenital Adrenal Hyperplasia Treatment Market

To lessen the symptoms of CAH, newborns with classic CAH should begin therapy as soon as possible after birth. Steroids are used to replace the low hormone levels in classic CAH. Hydrocortisone is a kind of cortisol that is commonly given to infants and children.

Adults are given hydrocortisone, prednisone, or dexamethasone to replace cortisol. Fludrocortisone is another medication used to substitute aldosterone in patients with classic CAH. Salt-wasters may benefit from eating salty foods or taking salt pills.

Patients with classic CAH must take medication on a regular basis for the rest of their lives. Symptoms will recur if a patient stops taking medication.

If a person has non-classic CAH and does not have symptoms, they may not require therapy. Individuals experiencing symptoms like early puberty, excess body hair, irregular menstrual periods, and infertility are given low doses of the same cortisol-replacement medicine as people suffering from typical CAH.

In the case of classic CAH, girls with ambiguous external genitalia may require surgery. For example, if genital alterations have impaired urine flow, surgery is required. Non-classic CAH girls have normal genitals and do not require surgery.

Emerging Congenital Adrenal Hyperplasia Treatment

A few clinical studies on CAH treatment are presently in progress are as follows:

• Alternative dosing forms of hydrocortisone with altered pharmacokinetics or easier dose titration.

• Corticotropin-releasing hormone receptor antagonists that reduce corticotropin (ACTH) secretion and thus adrenal androgen secretion.

• Androgen Biosynthesis Inhibitor

• Gene Therapy Vector

Alternative dosage forms of hydrocortisone are being offered or will be soon, although the cost could be a barrier to use, at least in the United States market. Corticotropin-releasing hormone receptor antagonists and androgen biosynthesis inhibitors are now being tested in clinical trials. 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global congenital adrenal hyperplasia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:  

• Neurocrine Bioscience

• Johnson and Johnson

• Sanofi

• Zydus Lifesciences Ltd.

• GSK plc

• BridgeBio, Inc

• Millendo Therapeutics, Inc.

• Spruce Biosciences

• EffRx Pharmaceuticals

Key Highlights of the Report